| Analyst |
Firm |
| Adam Cutler |
Canaccord Adams
|
| Leland Gershell |
Cowen & Co.
|
| Charles Duncan |
JMP Securities
|
| Cory Kasimov |
JPMorgan
|
| Matt Osborne |
Lazard
|
| William Tanner |
Leerink Swann
|
| Thomas McGahren |
Merrill Lynch
|
| Corey Davis |
Natixis
|
| Ruthanne Roussel |
The Robins Group
|
| Soham Pandya |
Think Equity
|
Orexigen Therapeutics, Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Orexigen Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Orexigen Therapeutics, Inc. or its management. Orexigen Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
|
0.44